2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study

EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study

Pdf Summary

This retrospective study investigated the impact of infusion timing of immune checkpoint inhibitor (ICI) monotherapy on clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Conducted at a single institution, the study included patients who received at least four ICI monotherapies between June 2016 and December 2021. Patients were divided into two groups: the "Early" group received 2 to 4 infusions before 11:45 am, and the "Delay" group received their infusions later.<br /><br />The study analyzed several outcomes, including the overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), using the Kaplan-Meier method and Cox proportional hazard model for survival analyses. Although patient characteristics varied slightly between the groups — with more low performance status, adenocarcinoma, and female cases in the Delay group — the backgrounds were nearly identical when considering response factors.<br /><br />Results showed no statistically significant differences between the groups. However, there was a trend indicating better survival outcomes (both PFS and OS) in the Early group. This trend is in line with previous studies suggesting better adaptive immune responses to treatment when administered earlier in the day.<br /><br />The findings propose that the initial timing of T-cell reinvigoration by ICIs might be critically important. Despite the lack of significant differences due to sample size limitations, these trends support the hypothesis that earlier administration of ICIs may enhance treatment efficacy. The study concludes that while retrospective, its insights are consistent with previous research, highlighting the potential need for prospective interventional studies to explore this timing effect further.

Asset Subtitle

Ryuta Tagawa

Meta Tag

Speaker Ryuta Tagawa

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immune checkpoint inhibitor

ICI monotherapy

non-small cell lung cancer

NSCLC

infusion timing

clinical outcomes

progression-free survival

overall survival

early administration

T-cell reinvigoration